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Abstract Since HIV-1 Tat has been associated with neuro-
cognitive dysfunction, we investigated 60 HIV-1 subtype
B-infected individuals who were characterized for neuro-
cognitive functioning and had paired CSF and blood
plasma samples available. To avoid issues with repeated
sampling, we generated population-based HIV-1 tat sequen-
ces from each compartment and evaluated these data using
a battery of phylogenetic, statistical, and machine learning
tools. These analyses identified position HXB2 5905 within
the cysteine-rich domain of tat as a signature of CSF-
derived HIV-1, and a higher number of mixed bases in CSF,
as measure of diversity, was associated with HIV-associated
neurocognitive disorder. Since identified mutations were
synonymous, we evaluated the predicted secondary RNA
structures, which showed that this mutation altered second-
ary structure. As a measure of divergence, the genetic
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distance between the blood and CSF-derived tat was
inversely correlated with current and nadir CD4+ T cell
counts. These data suggest that specific HIV-1 features of
tat influence neurotropism and neurocognitive impairment.
Keywords HIV. Central nervous system . tat .
Compartmentalization
Introduction
HIV-1 crosses the blood–brain barrier during primary
infection, eventually resulting in neurological complica-
tions in up to 50% of untreated individuals (Grant et al.
1987; Ho et al. 1985; Price 1996). Anatomic compartments
play an important role in the dynamics and evolution of
HIV, as distinct tissues provide different cellular targets,
immunologic pressures, and variations in drug concentra-
tion, thus driving viral evolution differently in various
compartments (Nickle et al. 2003). Previous reports have
shown that although each host’s viral population is
genetically distinct from populations in other individuals,
signature polymorphisms can be identified across hosts that
distinguish cerebrospinal fluid (CSF)-derived virus from
virus in the blood during clade B HIV infection (Pillai et al.
2006; Ritola et al. 2005; Strain et al. 2005). Additionally,
distinct reverse transcriptase and V3 genotypes are often
discordant between CSF and blood plasma virus (Pillai et
al. 2006; Wong et al. 1997), and analysis of positions in and
near the V3 loop of env have been associated with
impairment of neurocognitive performance (Pillai et al.
2006). Many of these previous studies were small (range 4–
27 subjects) and relied on the analysis of clonal sequences
to evaluate the viral populations in the anatomic compart-
ments, and these clonal sequences represent a form of
repeated measures, which can confound interpretation of
results (Choi et al. 2011). In this study, we evaluated a
larger sample and used population-based tat sequences to
investigate the viral genetic motifs associated with neuro-
cognitive impairment and anatomic compartment of origin.
Several viral and cellular factors contribute to the
neuronal damage after HIV-1 invasion into the brain (Kaul
et al. 2001). Among the viral factors, HIV proteins such as
Tat and Env are known to be neurotoxic in vitro (Kaul et al.
2001). In the brain, Tat may activate uninfected macro-
phages/microglia or astrocytes to release cytokines, chemo-
kines, or other toxins, which may adversely affect neuronal
function or apoptosis (Kruman et al. 1998; Li et al. 2009).
The Tat protein also has chemotactic properties for
monocytes (Albini et al. 1998), and the increased migration
of the activated monocytes to the brain is correlated with
HIV-associated neurocognitive disorder (HAND) (Kaul et
al. 2001). Also, several studies have compared HIV-1
subtypes B and C tat for their neuropathogeneic properties
(Mishra et al., 2008; Ranga et al., 2004), and a genetic
distinction between HIV-1 subtypes B and C in tat at
residue 31 where subtype C has a Cys and subtype B has a
serine has been implicated (Mishra et al., 2008; Ranga et
al., 2004). Specifically, Ranga et al. reported this difference
could result in the attenuation of chemotactic properties of
Tat (Ranga et al., 2004), and Mishra et al. suggested that
this mutation could attenuate the neurotoxic properties of
Tat (Mishra et al., 2008). In this, the largest study of HIV-1
tat to date, we investigated various viral characteristics of
HIV-1 subtype B tat that are associated with viral
populations in the blood and CSF and neurocognitive
dysfunction.
Results
Study cohort and rate of HAND
Of our 61 subjects, 60 had subtype B HIV-1 and one had
subtype D. Only those with subtype B infection contributed
to the overall analysis. Most were men (82%) with a mean
age of 41.9 years. Their mean current CD4+ T cell count
was 342 cells/μL, with a mean HIV RNA levels in CSF and
blood plasma of 3.6 and 4.7 log10copies/mL, respectively.
Thirty-six (60%) subjects were classified as having only
incidental comorbidities, and 17 (28.3%) had contributing
conditions; another 7 (11.7%) had confounding comorbid-
ities that could preclude a HAND diagnosis. At evaluation,
35% of total participants (21/60) were neuropsychologi-
cally impaired, and impairment rates in the comorbidity
groups were: 25% (9/36) incidental, 44% (8/18) contribut-
ing, and 57% (4/7) confounded. In univariate analysis, there
were no significant differences in demographic and clinical
characteristics such as age, sex, duration of education,
current and nadir CD4+ T cell counts, current plasma and
CSF HIV RNA levels, and CSF WBC counts between those
with and without neurocognitive impairments (Table 1). To
evaluate differences between subjects with HAND and
without HAND, we excluded the seven subjects with
confounding comorbidities, and in univariate analysis there
was no difference in the demographic and clinical character-
istics between those with and without HAND when those
with confounding comorbidities were excluded (Table 2).
Characteristics of CSF and blood-derived HIV-1 tat
For quality control, we performed phylogenetic analysis of
all sequences evaluated together, and as expected, CSF and
blood-derived HIV-1 tat sequences from the same subject
shared a most recent common ancestor (Fig. S1). Among
4320 amino acid positions (72 amino acid positions×60
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sequences) of paired CSF and blood tat sequences, 64
(1.5%) positions showed diversity. As a potential measure
of compartmentalization and divergence between blood and
CSF viral populations, we evaluated the genetic distances
between blood- and CSF-derived tat sequences and found
that the mean genetic distance between CSF and blood-
derived sequences was overall relatively close at 0.3±1.2%
(0–6.3%). Along these lines, we also performed selection
analysis using fixed effects likelihood (FEL; Kosakovsky
Pond and Frost. 2005) and identified five sites (codons T40,
N61, S62, Q66, and S68) that were inferred to be under
positive selection across all tat sequences but not specific to
viral populations derived from each compartment. As a
measure of viral population diversity (Poon et al. 2010) in
each compartment, we then investigated the number of total
mixed bases in each population-based sequence, and this
measure was also not different between CSF and blood-
derived tat sequences (2.52±2.12 and 2.52±2.76, P=0.39,
Mann–Whitney U test).
To look for evidence of a genetic signature shared by
CSF-derived sequences across individuals (i.e., potential
neurotropism), we employed a machine learning approach,
as previously described for env (Pillai et al. 2006). Different
from previous investigations, only one population-based tat
sequence per compartment of each subject was evaluated to
avoid the issue of repeated measures. This classification
model identified nucleotide position 75 (HXB2 position
5905) of tat as a genetic “signature” for viral populations
derived from the CSF (Fig. 1). Specifically, a thymine or
“Y” (mixed base of cytosine and thymine) at tat nucleotide
HXB2 position 5905 was significantly correlated with virus
derived from the CSF (P=0.03, Fisher’s exact test). The net
difference in site-specific variability between CSF and
blood (as measured by Shannon entropy) was also highest
at this position (Fig. 2). Since this mutation was a
synonymous or “silent” mutation, there was no phenotypic
signature associated with this mutation (Fig. S2).
Clinical correlates associated with tat
Similar to the methods described above, we then investi-
gated tat characteristics that were associated with HAND.
We found no signature residue or nucleotide position that
was associated with neurocognitive impairment or HAND,
and the genetic distance between CSF and blood-derived
sequences did not differ between subjects with and without
neurocognitive impairment or HAND (Tables 1 and 2).
However, the number of mixed bases in CSF (i.e., increased
viral population diversity) was significantly higher in
subjects with HAND than those without HAND (Table 2;








Age, mean years±SD 41.9±8.7 41.0±8.5 42.4±8.8 0.55
Sex, no. of male (%) 49 (82%) 17 (81%) 32 (82%) 0.92
Education, mean years±SD 12.3±2.6 12.0±2.5 12.4±2.7 0.59
Comorbidity subgroups, no. of subjects (%) 0.12
Incidental 36 (60%) 9 (43%) 27 (69%)
Contributing 17 (28%) 8 (38%) 9 (23%)
Confounding 7 (12%) 4 (19%) 3 (8%)
CSF HIV RNA, mean log10 copies/mL±SD 3.6±0.8 3.7±0.9 3.6±0.8 0.87
Plasma HIV RNA, mean log10copies/mL±SD 4.6±0.7 4.7±0.6 4.6±0.7 0.62
Current CD4+ T cell, mean cells/μL (range)±SD 342±216 348±242 339±204 0.88
Nadir CD4+ T cell counts, median cells/μL (range) 250±191 263±199 243±189 0.69
AIDS diagnosis, no. of subjects (%) 28 (47%) 9 (43%) 19 (49%) 0.79
Past ARV use, no. of subjects (%) 14 (23%) 7 (33%) 7 (18%) 0.21
CSF WBC counts, median cells/μL (IQR) 6.5 (3–14.25) 6 (3–20) 7 (3–14) 0.97
Mean genetic distance between CSF and blood-derived tat (%) 0.3% 0.4% 0.3% 0.83
Nucleotide at position 5905 of CSF-derived tat, no. of thymidine or Ya (%) 13 (22%) 6 (29%) 7 (18%) 0.35
Median no. of mixed bases in CSF-derived tat (IQR) 2b (0–3) 3b (1–5.5) 1b (0–3) 0.05*
Median no. of mixed bases in blood-derived tat (IQR) 2b (1–3.75) 2b (1–3.5) 2b (1–4) 0.77
ARV history of antiretroviral use, NC Neurocognitive
*P<0.05
aMixed base of cytosine and thymine
b The median number of mixed bases
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P=0.005 by Mann–Whitney U). Although not associated
with viral loads or neurocognitive impairment, the greater
the genetic distance between blood and CSF-derived
viruses, the lower the current and nadir CD4+ T cell counts
of participants (correlation coefficient=−0.281 and −0.284,
respectively, all P=0.03, Spearman’s rank correlation;
Tables 1 and 2).
Secondary RNA structures for HIV-1 B subtype tat
with and without a signature synonymous mutation
To better evaluate the possible changes associated with a
synonymous mutation being a signature for CSF-derived
virus, we next estimated changes in secondary RNA
structure associated with the C5905T motif. Secondary
RNA structures with lowest free energy for HIV-1 B
subtype tat (HXB2 position 5831–6046) and mutant tat
with the signature synonymous mutation (C5905T) were
predicted with the algorithm implemented in RNAstructure
v5.2 (Reuter and Mathews. 2010). Figure 3 shows that the
mutation altered the predicted secondary structure, but the
calculated free energy of two structures was not significantly
different (−53.3 kcal/mol for wild type and −51.9 kcal/mol for
mutant), which suggests that each structure is equally
valid. The substitution changed the shape and length of
two stems by pairing bases in the estimated stem
structure (Fig. 3).
Discussion
The HIV-1 tat sequence can be subdivided into distinct
regions on the basis of its amino acid composition: an N-
terminal activation region, a cysteine-rich role domain, a
core region, a basic region, and a glutamine-rich region
(Bayer et al. 1995). Each of these regions is essential for
Tat function. Among those, amino acid residues 22–38
comprise a highly conserved cysteine-rich domain of Tat.
The cysteine-rich domain seems to contribute to the
mechanism of Tat toxicity (Aksenov et al. 2009; Egele et
Fig. 1 Genetic signature associated with CSF sequences. The values
in parentheses are the number of instances/number of incorrect
classifications. Nucleotide position (5905) is based on HXB2 position
and one-letter nucleotide codes are used. Position 5905C was
associated with blood and 5905T or Y CSF
Table 2 Demographic, clinical, and viral characteristics of subjects without confounding comorbidities
Characteristics Overall (n=53) HAND (+) (n=17) HAND (−) (n=36) P value
Age, mean years±SD 42.3±8.8 42.1±8.5 42.4±9.1 0.90
Sex, no. of male (%) 43 (81%) 13 (76%) 30 (83%) 0.71
Education, mean years±SD 12.6±2.5 12.4±2.7 12.8±2.4 0.59
Comorbidity subgroups, no. of subjects (%) 0.13
Incidental 36 (68%) 9 (53%) 27 (75%)
Contributing 17 (32%) 8 (47%) 9 (25%)
CSF HIV RNA, mean log10 copies/mL±SD 3.7±0.8 3.8±0.9 3.6±0.8 0.48
Plasma HIV RNA, mean log10copies/mL±SD 4.7±0.7 4.8±0.6 4.6±0.7 0.41
Current CD4+ T cell, mean cells/μL (range)±SD 332±210 300±215 347±209 0.46
Nadir CD4+ T cell counts, median cells/μL (range) 240±186 220±180 249±190 0.61
AIDS diagnosis, no. of subjects (%) 25 (47%) 8 (47%) 17 (47%) 0.99
Past ARV use, no. of subjects (%) 14 (26%) 7 (41%) 7 (19%) 0.11
CSF WBC counts, median cells/μL (IQR) 7 (3–14) 5 (2–11) 7 (3–15) 0.67
Mean genetic distance between CSF and blood-derived tat (%) 0.3% 0.5% 0.3%, 0.61
Nucleotide at position 5905 of CSF-derived tat, no. of thymidine or Ya(%) 11 (21%) 5 (29%) 6 (17%) 0.30
Median no. of mixed bases in CSF-derived tat (IQR) 2b (0–3) 3b (1–7.5) 1b (0–3) 0.005*
Median no. of mixed bases in blood-derived tat (IQR) 2b (1–3) 3b (1–4.5) 2b (0.25–3) 0.36
ARV history of antiretroviral use, HAND HIV-associated neurocognitive disorder, “+” present, “−” absent
*P<0.05
aMixed base of cytosine and thymine
b The median number of mixed bases in sequences from each group
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al. 2008; Misumi et al. 2004), including neurotoxicity in
vitro (Li et al. 2009; Nath et al. 1996). A substitution of a
specific cysteine within this domain significantly attenuated
its neurotoxicity (Aksenov et al. 2009), and the lower
neurotoxic potential of clade C HIV-1 has implicated a
mutation of cysteine 31 within this domain (Mishra et al.
2008; Ranga et al. 2004). In this study, we identified a
nucleotide position (HXB2 position 5905) within the
cysteine-rich domain as a synonymous signature of CSF-
derived subtype B HIV-1. However, the biological signif-
icance of the synonymous mutation remains unclear.
The cysteine-rich domain of Tat is highly conserved and
might serve as a binding domain for zinc-mediated linkage
of Tat monomers (Frankel et al. 1988; Huang and Wang.
1996). While a silent mutation within the region might not
affect zinc binding, synonymous changes can alter RNA
secondary structure and influence RNA stability (Watts et
al. 2009). RNA secondary structure plays an important role
in the HIV life cycle (Berkhout. 1992; Galetto et al. 2004;
Parkin et al. 1992; Wang et al. 2008), and we showed that
the HXB2 position 5905 mutations altered the predicted
secondary RNA structure including the shape and length of
stems. At present, we do not have informative data with
respect to whether the RNA secondary structure affects tat
function and neurotoxicity. In vitro mutagenesis studies
might identify the functional significance of this mutation.
Compartmentalization of HIV-1 env (Power et al. 1994;
Ritola et al. 2005; Strain et al. 2005) and diversity of env
and pol (Hightower et al. 2011) have been associated with
HAND. Standard evaluation of both anatomic compart-
mentalization and diversity has required single genome
sequencing, clonal amplification and ultra-deep sequencing,
but these resource intensive methods are complicated by
issues of repeated sampling (Choi et al. 2011). To address
these methodological limitations, we used population-based
sequences derived from both blood and CSF HIV RNA
populations and then measured: (1) the genetic distance
between CSF and blood-derived sequences as a measure of
divergence and surrogate for compartmentalization, and (2)
the total mixed base index (a count of total mixed bases
divided by the sequence length) as measure of diversity. In
this study, the median number of mixed bases of CSF-
derived tat was significantly higher among subjects with
HAND, which suggests HIV population diversity of tat
most likely correlates with HAND. The genetic distance
between blood and CSF-derived sequences, as a measure of
potential compartmentalization, however, was not signifi-
cantly associated with HAND. Interestingly, genetic dis-
tance between blood and CSF-derived viruses was
inversely correlated with current and nadir CD4+ T cell
counts, and may provide evidence of correlation between
duration of infection, disease progression, and viral evolu-
tion in anatomic compartments (Keys et al. 1993). Further,
a previous report that lower CD4 counts are associated with
greater autonomous CNS production of HIV is also
consistent with this observation (Robertson et al. 2007).
As a hypothesis, viral adaptation that occurs separately in
blood and CSF compartments demonstrates a phenotype
that is most identifiable as a drop in CD4 counts (i.e., blood
adaptation) than a decline in neurocognitive functioning (i.e.,
CNS adaptation), and low CD4 counts might increase the risk
for neuroadaptation but neuroadaptation may not be sufficient
to cause neurovirulence.
To our knowledge, this is the largest study of its kind
investigating HIV-1 tat. The reported trends are consistent
with previous studies investigating other coding regions,
but similar to previous studies, this study is also most likely
limited by the relatively small number of subjects. In
summary, nucleotide position (HXB2 position 5905) within
the cysteine-rich domain appears to be a signature of CSF-
derived HIV-1, and HIV population diversity of tat seems










Fig. 2 Difference in Shannon
entropy between CSF- and
blood-derived tat sequences.
Position 5905 (circle) of HIV-1
tat had the greatest difference in
Shannon entropy between CSF
and blood. Y-axis (Entropy dif-
ference) represents the entropy
difference between CSF and
blood
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distance between the blood and CSF-derived tat was not
associated with neurocognitive impairment, it was in-
versely correlated with current and nadir CD4+ T cell
counts. The biological significance of the 5905 mutation is
unclear, but this study provides evidence that it is




Sixty-one individuals enrolled in the CNS HIV Antiretro-
viral Therapy Effects Research (CHARTER) cohort be-
tween 2002 and 2009 were examined (Heaton et al. 2010).
No subjects took antiretroviral therapy for at least 2 months
before specimen collection, had blood plasma HIV RNA of>
500 copies/mL, and no evidence of systemic or CNS
opportunistic infections or malignancy based on clinical,
laboratory, and/or neuroimaging studies. Subjects were
selected from the cohort for having matched plasma and
CSF available and having detectable plasma and CSF viral
loads. Blood was collected in acid citrate dextrose tubes and
CSF was collected without additive within 1 h from
venipuncture. Blood plasma and cell-free CSFwere aliquoted,
frozen, and stored at −80°C until processing.
Neurobehavioral assessment
Subjects completed a detailed neuropsychological assess-
ment measuring their functioning in seven cognitive
domains known to be commonly affected by HIV: verbal
fluency, executive functioning, speed of information pro-
cessing, learning, recall, working memory, and motor skill,
as previously described (Moore et al. 2010; Woods et al.
2004). The best available normative standards were used,
which correct for effects of age, education, sex, and
ethnicity, as appropriate. Test scores were converted to
demographically corrected standard scores (t scores). To
classify presence and severity of neurocognitive impair-
ment, we applied an objective algorithm shown to yield
excellent interrater reliability (Woods et al. 2004). This
algorithm conforms to the Frascati criteria for diagnosing
HAND (Antinori et al. 2007), which requires presence of at
least mild impairment in at least two of the seven ability
domains. All sub-classification of HAND require a deter-
mination that the neurocognitive impairment and functional
disability are believed to be due to effects of HIV on the
brain, and are not readily attributable to a comorbid
condition. To facilitate interrater reliability of these deter-
minations, we utilized the online supplement to the
previous report (Antinori et al. 2007), which provided
detailed guidelines for classifying the most commonly
encountered comorbid conditions with respect to whether
they should be considered incidental, contributing, or
confounding (Heaton et al. 2010).
Nucleotide sequencing
HIV-1 RNA was extracted and quantified from 500 μL of
blood plasma and from 500 μL of CSF using the QIAmp
Viral RNA Mini Kit (QIAGEN, Valencia, CA) according to
the manufacturer’s instructions. Reverse transcription of
HIV-1 RNA extracted from blood and CSF to make cDNA
was accomplished using RETROscript kit per the manu-
facturer’s instructions (Applied Biosystems). Then 5 μl of
blood HIV cDNA underwent PCR with primers and
conditions specific for HIV-1 tat for sequencing (Yukl et
al. 2009). All PCR products were sequenced using Prism
Dye terminator kits (ABI) on an ABI 3100 Genetic
Analyzer. The tat sequences of subjects have been
submitted to GenBank (GenBank ID: JF338918-JF339037).
Sequence analysis
Sequences were initially edited and aligned by Clustral W
(Thompson et al. 1994). The alignment was then manually
edited in Bioedit, version 7.05 to preserve frame insertions
and deletions if present (Hall 1999). Phylogenetic trees
were generated from tat sequences that were obtained from
a matrix of synonymous nucleotide distances using the
Hasegawa-Kishino-Yang model of evolution with a 4:1
ratio of transversion to transitions in the PhyML program
on Los Alamos National Laboratory HIV Sequence Database
website (http://www.hiv.lanl.gov/content/sequence/PHYML/
interface.html, accessed 15 January 2011; Guindon et al.
2005). Pairwise distance was calculated by Tamura-Nei (93)
estimator using HyPhy package (Pond et al. 2005). Sequen-
ces were examined for inter-subtype recombination, using
RIP 3.0 (http://www.hiv.lanl.gov/content/sequence/RIP/RIP.
html, accessed 15 December 2010), and conserved residues
using VESPA (http://www.hiv.lanl.gov/content/sequence/
VESPA/vespa.html, accessed 15 December 2010; Korber
and Myers. 1992). All classification experiments in this
analysis were conducted using WEKA (Waikato Environ-
ment for Knowledge Analysis), an open-source collection of
data processing and machine learning algorithms (Witten and
Frank. 2000). The J48 decision tree inducer, based on the
C4.5 algorithm, was implemented with the parameter
“MinNumObj” set at a value of 11 to limit the complexity
of theories and minimize the risk of over-fitting (Baliga et al.
Fig. 3 Secondary RNA structures for wild-type tat of HIV-1 subtype
B(HXB2) (a) and mutant tat with the CSF-signature synonymous
mutation (C5905T) (b)

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1992). Classifiers were evaluated using 100 iterations of
stratified tenfold cross-validations, a procedure designed to
conservatively reflect the performance of classification
models on novel data sets (Witten and Frank. 2000).
Shannon entropy was calculated to identify signatures of
CSF-derived HIV-1 tat, using Entropy (http://www.hiv.lanl.
gov/content/sequence/ENTROPY/entropy.html, accessed 15
December 2010). The residue specific entropy was computed
from the frequency f(Ai) of amino acid A at position i
according to PAf Aið Þln f Aið Þ½  (Reza. 1994). A batch
file implemented in HyPhy was used to provide a
measure of viral population diversity by counting total
mixed bases, synonymous mixed bases, and non-
synonymous mixed bases (Pond et al. 2005; Hightower
et al. 2011). FEL methods identified purifying and
diversifying selection across the phylogeny (FEL) and
along internal branches (iFEL). Model selection was used
to select a DNA substitution model, evidence for
recombination was evaluated with GARD (Kosakovsky
Pond et al. 2006), and analyses were implemented in
web-based Datamonkey (accessed December 10, 2010;
Pond and Frost. 2005). Secondary RNA structures with
lowest free energy for the firsr exon of wild-type tat
(HXB2 position 5831–6046) and mutant tat with signa-
ture non-synonymous mutations were predicted with the
algorithm implemented in RNAstructure v5.2 (Reuter and
Mathews. 2010).
Statistical analysis
Fisher’s exact test was used to compare categorical or
binary measures, and independent t tests or Mann–Whitney
U tests were used to compare continuous variables. Spear-
man’s rank correlation was used to evaluate correlations
between continuous variables. All P values were two-tailed
and P<0.05 was considered statistically significant. All
analyses were performed using SPSS for Windows 12.0
(SPSS, Chicago, Illinois, USA).
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